Zhejiang Jianfeng Group Co., Ltd. Third Quarter Report 2018 Text
Release time:
2020-07-07
公司代码:600668 公司简称:尖峰集团
浙江尖峰集团股份有限公司
2018年第三季度报告正文
一、 重要提示
1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。
1.2 公司全体董事出席董事会审议季度报告。
1.3 公司负责人蒋晓萌、主管会计工作负责人兰小龙及会计机构负责人(会计主管人员)吴德富保证季度报告中财务报表的真实、准确、完整。
1.4 本公司第三季度报告未经审计。
二、 公司主要财务数据和股东变化
2.1 主要财务数据
单位:元 币种:人民币
|
|
本报告期末 |
上年度末 |
本报告期末比上年度末增减(%) |
|
总资产 |
4,787,531,214.62 |
4,175,730,846.73 |
14.65 |
|
归属于上市公司股东的净资产 |
3,091,664,703.46 |
2,627,318,888.65 |
17.67
|
|
|
年初至报告期末 (1-9月) |
上年初至上年报告期末 (1-9月) |
比上年同期增减(%) |
|
经营活动产生的现金流量净额 |
375,343,924.71 |
194,680,761.60 |
92.80 |
|
|
年初至报告期末 (1-9月) |
上年初至上年报告期末 (1-9月) |
比上年同期增减 (%) |
|
营业收入 |
2,308,365,252.61 |
1,966,202,048.98 |
17.40 |
|
归属于上市公司股东的净利润 |
488,183,289.95 |
291,408,643.10 |
67.53 |
|
归属于上市公司股东的扣除非经常性损益的净利润 |
473,663,318.81 |
277,934,952.23 |
70.42 |
|
加权平均净资产收益率(%) |
17.05 |
11.74 |
增加5.31个百分点 |
|
基本每股收益(元/股) |
1.4188 |
0.8469 |
67.53 |
|
稀释每股收益(元/股) |
1.4188 |
0.8469 |
67.53 |
非经常性损益项目和金额
单位:元 币种:人民币
|
项目 |
本期金额 (7-9月) |
年初至报告期末金额(1-9月) |
说明 |
|
非流动资产处置损益 |
17,071.47 |
25,797.10 |
|
|
越权审批,或无正式批准文件,或偶发性的税收返还、减免 |
1,344,590.41 |
2,037,104.39 |
|
|
计入当期损益的政府补助,但与公司正常经营业务密切相关,符合国家政策规定、按照一定标准定额或定量持续享受的政府补助除外 |
6,010,443.10 |
15,471,116.32 |
|
|
委托他人投资或管理资产的损益 |
169,552.87 |
1,535,544.14 |
|
|
除上述各项之外的其他营业外收入和支出 |
-24,177.80 |
-680,195.47 |
|
|
少数股东权益影响额(税后) |
-346,385.71 |
-472,835.16 |
|
|
所得税影响额 |
-1,511,067.33 |
-3,396,560.18 |
|
|
合计 |
5,660,027.01 |
14,519,971.14 |
|
2.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)持股情况表
单位:股
|
股东总数(户) |
29,258 |
||||||
|
前十名股东持股情况 |
|||||||
|
股东名称 (全称) |
期末持股数量 |
比例(%) |
持有有限售条件股份数量 |
质押或冻结情况 |
股东性质 |
||
|
股份状态 |
数量 |
||||||
|
金华市通济国有资产投资有限公司 |
55,564,103 |
16.15 |
0 |
无 |
0 |
国有法人 |
|
|
国通信托有限责任公司-国通信托·惠钰1号单一资金信托 |
9,234,900 |
2.68 |
0 |
无 |
0 |
未知 |
|
|
国民信托有限公司-国民信托·华富3号证券投资单一资金信托 |
6,922,000 |
2.01 |
0 |
无 |
0 |
未知 |
|
|
香港中央结算有限公司 |
4,510,078 |
1.31 |
0 |
无 |
0 |
未知 |
|
|
浙江康恩贝制药股份有限公司 |
3,742,992 |
1.09 |
0 |
无 |
0 |
境内非国有法人 |
|
|
何文康 |
3,439,100 |
1.00 |
0 |
无 |
0 |
境内自然人 |
|
|
王晓红 |
3,121,943 |
0.91 |
0 |
无 |
0 |
境内自然人 |
|
|
骆惠娟 |
2,976,200 |
0.86 |
0 |
无 |
0 |
境内自然人 |
|
|
钟以隆 |
2,650,000 |
0.77 |
0 |
无 |
0 |
境内自然人 |
|
|
徐新华 |
2,544,661 |
0.74 |
0 |
无 |
0 |
境内自然人 |
|
|
前十名无限售条件股东持股情况 |
|||||||
|
股东名称 |
持有无限售条件流通股的数量 |
股份种类及数量 |
|||||
|
种类 |
数量 |
||||||
|
金华市通济国有资产投资有限公司 |
55,564,103 |
人民币普通股 |
55,564,103 |
||||
|
国通信托有限责任公司-国通信托·惠钰1号单一资金信托 |
9,234,900 |
人民币普通股 |
9,234,900 |
||||
|
国民信托有限公司-国民信托·华富3号证券投资单一资金信托 |
6,922,000 |
人民币普通股 |
6,922,000 |
||||
|
香港中央结算有限公司 |
4,510,078 |
人民币普通股 |
4,510,078 |
||||
|
浙江康恩贝制药股份有限公司 |
3,742,992 |
人民币普通股 |
3,742,992 |
||||
|
何文康 |
3,439,100 |
人民币普通股 |
3,439,100 |
||||
|
王晓红 |
3,121,943 |
人民币普通股 |
3,121,943 |
||||
|
骆惠娟 |
2,976,200 |
人民币普通股 |
2,976,200 |
||||
|
钟以隆 |
2,650,000 |
人民币普通股 |
2,650,000 |
||||
|
徐新华 |
2,544,661 |
人民币普通股 |
2,544,661 |
||||
|
上述股东关联关系或一致行动的说明 |
本公司第一大股东通济国投与其他上述第2名至第10名无限售条件股东之间不存在关联关系。公司未知其他9名股东之间是否存在关联关系,也未知是否属于《上市公司收购管理办法》规定的一致行动人。 |
||||||
|
表决权恢复的优先股股东及持股数量的说明 |
不适用 |
||||||
2.3 截止报告期末的优先股股东总数、前十名优先股股东、前十名优先股无限售条件股东持股情况表
三、 重要事项
3.1 公司主要会计报表项目、财务指标重大变动的情况及原因
|
资产负债表项目 |
期末数(万元) |
期初数(万元) |
变动幅度 |
变动原因 |
|
预付帐款 |
10,245.02 |
4,610.82 |
122.20% |
主要系本报告期子公司预付货款增加所致。 |
|
其他应收款 |
2,095.55 |
1,308.75 |
60.12% |
主要系报告期公司的投资单位已宣告但尚未发放的现金股利增加所致。 |
|
其他流动资产 |
14,482.18 |
1,328.92 |
989.77% |
主要系报告期公司购买的短期银行结构性存款理财产品所致。 |
|
投资性房地产 |
7,964.52 |
2,145.61 |
271.20% |
主要系报告期子公司尖峰国贸在建电商物流园项目部分结转增加所致。 |
|
在建工程 |
2,542.40 |
4,557.67 |
-44.22% |
主要系报告期子公司在建工程项目部分结转相应资产所致。 |
|
商誉 |
7,549.90 |
1,629.86 |
363.22% |
主要系报告期公司新增合并企业上海北卡所致。 |
|
长期待摊费用 |
244.21 |
175.03 |
39.52% |
主要系报告期公司新增合并企业上海北卡所致。 |
|
短期借款 |
14,900.00 |
8,900.00 |
67.42% |
主要系报告期公司及子公司增加银行借款所致。 |
|
应付职工薪酬 |
1,267.86 |
3,627.55 |
-65.05% |
主要系报告期公司及子公司发放上年末计提的年终奖所致。 |
|
其他应付款 |
28,672.64 |
17,432.86 |
64.47% |
主要系报告期子公司计提的市场推广费和其他支出增加及子公司股东会决议宣告但尚未发放的2017年度现金股利增加所致。 |
|
一年内到期的非流动负债 |
0.00 |
27,631.69 |
-100.00% |
主要系报告期公司按期兑付到期的公司债券所致。 |
|
长期借款 |
13,200.00 |
0.00 |
100.00% |
主要系报告期公司新增的长期银行借款及新增合并企业众望制药所致。 |
|
少数股东权益 |
27,469.76 |
19,695.14 |
39.47% |
主要系报告期公司新增合并企业上海北卡所致。 |
|
利润表项目 |
本期数(万元) |
上年同期数(万元) |
变动幅度 |
变动原因 |
|
税金及附加 |
2,156.55 |
1,414.54 |
52.46% |
主要系报告期子公司营业收入增加相应的税金及附加增加所致。 |
|
销售费用 |
34,510.47 |
19,767.16 |
74.58% |
主要系报告期子公司尖峰药业销售收入的增长和销售模式的调整,公司销售费用中相应增加了市场推广费和其他支出。 |
|
投资收益 |
17,306.51 |
10,365.66 |
66.96% |
主要系报告期公司联营投资单位南方尖峰水泥有限公司利润大幅增长,公司权益法核算计入投资收益相应增加所致。 |
|
所得税费用 |
11,927.05 |
7,392.18 |
61.35% |
主要系本报告期子公司实现的利润总额增加相应的所得税费用增加所致。 |
|
现金流量表项目 |
|
|
|
|
|
经营活动产生的现金流量净额 |
37,534.39 |
19,468.08 |
92.80% |
主要系报告期公司销售收入增长及营业利润大幅增加所致。 |
|
投资活动产生的现金流量净额 |
-24,857.50 |
-21,162.20 |
|
|
|
筹资活动产生的现金流量净额 |
-19,354.57 |
-5,320.98 |
|
主要系报告期公司到期兑付了公司债券本金及利息所致。 |
3.2 重要事项进展情况及其影响和解决方案的分析说明
1.2017年8月3日,本公司九届14次董事会通过了《关于山亚南方股权重组的关联交易的议案》。
本公司控股子公司尖峰水泥持有南方尖峰35%股权,金华南方水泥有限公司(以下简称“金华南方”)持有南方尖峰65%股权;南方尖峰持有杭州山亚南方水泥有限公司(以下简称“山亚南方”)的100%股权。为了压减企业层级、提高运营效率,拟对山亚南方进行股权重组,南方尖峰将所持有的山亚南方100%股权上移,分别转让给尖峰水泥与金华南方两个股东,尖峰水泥与金华南方按所占南方尖峰的股权比例受让山亚南方股权,其中:尖峰水泥拟出资62,099,765元受让山亚南方的35%股权;金华南方拟出资115,328,135元受让山亚南方的65%股权。股权重组完成后,山亚南方的股权层级将上移,重组前后本公司所持该股权的整体权益没有变化。详见2017年8月3日本公司在上海证券交易所网站披露的临2017-019《关于山亚南方股权重组的关联交易公告》。截止报告期末,因支付股权转让款的前提条件尚未达到,该股权重组事项尚未实施。该事项不会影响公司所持的该股权的整体权益。
2.2018年8月3日,公司十届5次董事会通过了《关于子公司尖峰药业对上海北卡增资的议案》本公司控股子公司尖峰药业出资人民币5000万元,自然人吴江出资人民币1000万元,对上海北卡进行增资,其他股东放弃参与本次增资。上述事项详见2018年8月4日本公司披露于上海证券交易所网站(http//:www.sse.com.cn/)的临2018-022《十届5次董事会决议公告》和临2018-025《关于子公司尖峰药业对上海北卡增资的公告》。截止报告期末,本次增资事宜已经完成,上海北卡已经完成了工商变更登记手续。上海北卡注册资本由原来的1755.55万元增加至2275.93万元,其中尖峰药业占61.48%。
3. 2018年8月3日,公司十届5次董事会通过了《关于子公司上海北卡收购安徽众望的议案》。本公司控股子公司上海北卡医药技术有限公司出资2062万元,收购安徽众望制药有限公司的全部100%股权,收购完成后安徽众望将成为上海北卡的全资子公司。上述事项详见2018年8月4日本公司披露于上海证券交易所网站(http//:www.sse.com.cn/)的临2018-022《十届5次董事会决议公告》和临2018-023《关于子公司上海北卡收购安徽众望的公告》。截止报告期末,该股权收购事宜已经完成,安徽众望已经完成工商变更登记手续,成为上海北卡的全资子公司。
4. 2018年8月3日,公司十届5次董事会通过了《关于尖峰药业金西生产基地年产20亿片固体制剂项目的议案》,同意尖峰药业投资建设金西生产基地年产20亿片固体制剂项目。上述事项详见2018年8月4日本公司披露于上海证券交易所网站(http//:www.sse.com.cn/)的临2018-022《十届5次董事会决议公告》和临2018-024《关于尖峰药业金西生产基地年产20亿片固体制剂项目的公告》。截止报告期末,金西生产基地年产20亿片固体制剂项目的土地指标已经落实,主体工艺设备选型基本完成,工艺设计正在进行中。
5.2017年2月29日,公司九届十次董事会审议通过的《关于子公司对外投资的议案》,本公司控股子公司浙江尖峰药业有限公司拟以增资和股权转让的方式,分期对北京慧宝源生物技术股份有限公司进行投资,其中:第一期出资8,000万元,以每股4元的价格对慧宝源生物增资2,000万股;第二期出资8,600万元,以每股4.30元的价格对慧宝源生物增资2,000万股,另出资3,010万元以每股4.30元的价格受让桂林商源出让的慧宝源生物股权700万股;第三、第四期各对慧宝源生物增资1,400万股,增资价格以届时各方共同认可并聘请的具有证券从业资格的资产评估机构进行评估,以评估结果为基础协商确定。截止报告期末,浙江尖峰药业有限公司已完成了第一期出资,占北京慧宝源生物技术股份有限公司20%的股权。
3.3 报告期内超期未履行完毕的承诺事项
3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变动的警示及原因说明
|
公司名称 |
浙江尖峰集团股份有限公司 |
|
法定代表人 |
蒋晓萌 |
|
日期 |
2018年10月30日 |
- 发布时间: 2018-10-31
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11